Patients’ stem cells point to potential treatments for motor | Cosmos – Cosmos

Physicist Stephen Hawking is perhaps the most famous sufferer of motor neuron disease, a crippling degenerative condition that affects an estimated 150,00 people around the world.

Karwai Tang / Getty

In news that may bring hope to Stephen Hawking and hundreds of thousands of others around the world, British scientists have used reprogrammed skin cells to study the development of motor neuron disease.

Its like changing the postcode of a house without actually moving it, explains neuroscientist Rickie Patani, referring to research offering startling new insights into the progress and treatment of the crippling degenerative condition, also known as amyotrophic lateral sclerosis (ALS).

Patani, together with colleague Sonia Gandhi, both from the Francis Crick Institute and University College London, in the UK, led a team of researchers investigating how the disease destroys the nerve cells that govern muscle movement.

The results, published in the journal Cell Reports, comprise the most fine-grained work to date on how ALS operates on a molecular level and suggest powerful new treatment methods based on stem cells.

Indeed, so exciting are the implications of the research that Ghandi and Patani are already working with pharmaceutical companies to develop their discoveries.

The neurologists uncovered two key interlinked interactions in the development of motor neuron disease, the first concerning a particular protein, and the second concerning an auxiliary nerve cell type called astrocytes.

To make their findings, the team developed stem cells from the skin of healthy volunteers and a cohort carrying a genetic mutation that leads to ALS. The stem cells were then guided into becoming motor neurons and astrocytes.

We manipulated the cells using insights from developmental biology, so that they closely resembled a specific part of the spinal cord from which motor neurons arise, says Patani.

We were able to create pure, high-quality samples of motor neurons and astrocytes which accurately represent the cells affected in patients with ALS."

The scientists then closely monitored the two sets of cells healthy and mutated to see how their functioning differed over time.

The first thing they noted was that a particular protein TDP-43 behaved differently. In the patient-derived samples TDP-43 leaked out of the cell nucleus, catalysing a damaging chain of events inside the cell and causing it to die.

The observation provided a powerful insight into the molecular mechanics of motor neuron disease.

Knowing when things go wrong inside a cell, and in what sequence, is a useful approach to define the critical molecular event in disease, says Ghandi.

One therapeutic approach to stop sick motor neurons from dying could be to prevent proteins like TDP-43 from leaving the nucleus, or try to move them back.

The second critical insight was derived from the behaviour of astrocytes, which turned out to function as a kind of nursemaid, supporting motor neuron cells when they began to lose function because of protein leakage.

During the progression of motor neuron disease, however, the astrocytes like nurses during an Ebola outbreak eventually fell ill themselves and died, hastening the death of the neurons.

To test this, the team did a type of mix and match exercise, concocting various combinations of neurons and astrocytes from healthy and diseased tissue.

They discovered that healthy astrocytes could prolong the functional life of ALS-affected motor neurons, but damaged astrocytes struggled to keep even healthy motor neurons functioning.

The research reveals both TDP-43 and astrocytes as key therapeutic targets, raising the possibility that the progress of ALS might be significantly slowed, or perhaps even halted.

Our work, along with other studies of ageing and neurodegeneration, would suggest that the cross-talk between neurons and their supporting cells is crucial in the development and progression of ALS, says Patani.

Here is the original post:
Patients' stem cells point to potential treatments for motor | Cosmos - Cosmos

BioEden – Autistic Children’s Early Success Stories From Tooth Stem Cells – PR Newswire (press release)

- More and more people retrieve their banked cells and benefit from clinical treatments

Twenty individuals, ranging from the ages of 2 to 43, have become the first to use stem cells from their teeth in the treatment of various conditions including cerebral palsy, diabetes, cleft lip, and autism. The cells in use are dental pulp stem cells (DPSCs) - the richest source of MSCs in the body - extracted from the likes of exfoliated incisors, deciduous or baby, and wisdom teeth.

All patients report no adverse reactions, with several experiencing huge improvements in their conditions. To date, all treatments worked as well if not better than traditional treatments, but by far the most promising results are being seen in children with autism.

A complex behavioural disorder that affects 1 in every 100 people in the UK, autism is one of the biggest challenges that faces modern medicine today. Not only do symptoms manifest differently in each patient, but there is no one definitive cause. To treat an individual requires a tailored combination of therapies and medications - often meaning years of harsh drugs and hours of intensive behavioural therapy.

Many experts believe stem cell therapy can change that, or at least help children along the way, and several recent studies are proving their intentions are more than good-hearted. Their case is based on the rationale that autism is caused, in part, by inflammation in the body. And a particular type of stem cells, known as mesenchymal stem cells (MSCs), is able to reduce that inflammation.

Our teeth are not only richer in MSCs than bone marrow or cord blood, but the process of extraction also costs less and can be done so non-invasively, using naturally fallen teeth. This makes it an easy and completely pain-free process. You don't even have to see the inside of a hospital or clinic - just send the tooth to the bank, and they will do the rest.

And that's exactly what the parents of five children with autism did. Having originally sent teeth of all shapes and sizes to BioEden, the world's first tooth stem cell bank, they've now retrieved their cells and the children are involved in various stages of cell-based therapies.

Reports from one 11-year-old show how developmental markers across the board improved after just 10 weeks of treatment. Progress has been made in language, driving motility, communication with the environment, and memory and retention, and they're getting ready for their second round of treatment this year.

In another case of an 11-year-old, the child didn't speak before the treatment but now has a vocabulary of 15 words. Other improvements among the five children include better memory, mobility, and bodily control, more energy, a new sensitivity to pain, and physical growth. It's clear autism responds well to tooth cells.

Tooth stem cell banking offers patients a convenient and risk-free alternative to cord blood banking for example and bone marrow aspiration. By not throwing away those shedded baby teeth and instead sending them to a specialist tooth bank, you can arm yourself with a powerful resource and help safeguard a children's future health.

BioEden is a specialist banking facility that does not directly participate in or encourage its customers to seek therapies. The determination as to whether stem cell therapy may be useful to treat a particular condition is a decision that must be made between the patient and their treating physician.

Contact: Leon Staff Tel.: +44-208-4770-336 Email: info@bioeden.co.uk

Website: http://www.bioeden.com

SOURCE BioEden

Read the original here:
BioEden - Autistic Children's Early Success Stories From Tooth Stem Cells - PR Newswire (press release)

Promising possibilities of stem cell research explored at UCalgary event – UCalgary News

Calgary aviation engineer Don Adamson endured a dozen surgeries to keep him alive after a car fire burned 50 per cent of his body.

Adamson remembers paramedics thinking he was dead that day 12 years ago. But he fought back, survived and today is one of the biggest advocates for stem cell researchresearch he believes will eventually improve the quality of life of burn survivors.

Skin grafts just patch you up, and stop the bleeding, he says. Using stem cells potentially enable skin regeneration that will help future burn patients both function and look better.

Adamsons confidence in the research being done into potential clinical applications of stem cells foundation cells for every body organ and tissue that also work to maintain and repair the body throughout life comes, in large part, from his association with University of Calgary Faculty of Veterinary Medicine (UCVM) researcher Jeff Biernaskie.

Biernaskie, who is an associate professor in UCVMs Department of Comparative Biology and Experimental Medicine, is the Calgary Firefighters Burn Treatment Society Chair in Skin Regeneration and Wound Healing. He holds a joint appointment in the Cumming School of Medicine Department of Surgery and is a member of the Alberta Childrens Hospital Research Institute.

In 2014, Biernaskies lab identified the existence of a dermal stem cell in adult hair follicles, a discovery that shed new light on how hair follicles regenerate. His team of multidisciplinary collaborators is studying how that discovery can be used to repair wounded human skin.

Its application would be life-changing for millions of burn victims (30 per cent of whom are children), military personnel hurt in action, and the elderly whose paper-thin skin doesnt heal well.

High school students and adults learn about stem cell research

Adamson and Biernaskie were among the speakers at 5th Annual StemCell Talks, a symposium organized by university students. Nearly 180 students from 15 high schools learned about current stem cell research from cell transplants to treat chronic complications of diabetes, and stem cells for healthy organ creation, to career options related to stem cell science.

For Sana Jawad, a Grade 12 student at Sir Winston Churchill high school, the symposium opened her eyes to a potential research career. Already slated for biological sciences at UCalgary, Jawad was inspired by Adamsons burn survival story.

I thought research would be boring. But I realize now there are real people involved that what you do with science can make a big difference in their lives.

An evening adult session also attracted nearly 100 attendees from the Calgary community interested in learning more about stem cell basics, their potential for future clinical use, as well as their many limitations.

Modern day snake oil salesmen putting desperate sick people at risk

Attendees learned about the health threat posed by what are known as "medical tourism clinics" operating in a variety of countries (including Canada) that claim to heal everything from arthritis, Alzheimers and multiple sclerosis, to heart disease and Parkinsons through unproven stem cell treatments.

Part of Adamsons stem cell research advocacy includes taking on modern day snake oil salesmen in clinics that perpetuate myths of stem cell miracles that can save those desperate for cures.

Ubaka Ogbogu, assistant professor at the University of Alberta, who also spoke at the event, was equally blunt: They are hucksters.

Ogbogu cited cases where desperate, sick people mortgaged their homes to spend tens of thousands of dollars on treatments that only made them worse. He said the clinics take evolving research into private care ahead of science, without proof it is safe or works.

He estimates it will be another 30 years of research (including taking testing from the laboratory to human trials), government approvals and new drug development before legitimate stem cell therapies could be available.

Biernaskie is more optimistic (10-20 years) but agrees, saying scientists are moving forward, but cautiously, because the right types of cells need to be made and then successfully integrated within the human body and they need to restore function. Most importantly, we need to be sure they wont harm the patient.

Read more here:
Promising possibilities of stem cell research explored at UCalgary event - UCalgary News

Trials of Embryonic Stem Cells to Launch in China – Scientific American

In the next few months, surgeons in the Chinese city of Zhengzhou will carefully drill through the skulls of people with Parkinsons disease and inject 4 million immature neurons derived from human embryonic stem cells into their brains. Then they will patch the patients up, send them home and wait.

This will mark the start of the first clinical trial in China using human embryonic stem (ES) cells, and the first one worldwide aimed at treating Parkinsons disease using ES cells from fertilized embryos. In a second trial starting around the same time, a different team in Zhengzhou will use ES cells to target vision loss caused by age-related macular degeneration.

The experiments will also represent the first clinical trials of ES cells under regulations that China adopted in 2015, in an attempt to ensure the ethical and safe use of stem cells in the clinic. China previously had no clear regulatory framework, and many companies had used that gap as an excuse to market unproven stem-cell treatments.

It will be a major new direction for China, says Pei Xuetao, a stem-cell scientist at the Beijing Institute of Transfusion Medicine who is on the central-government committee that approved the trials. Other researchers who work on Parkinsons disease, however, worry that the trials might be misguided.

Both studies will take place at the First Affiliated Hospital ofZhengzhouUniversity in Henan province. In the first, surgeons will inject ES-cell-derived neuronal-precursor cells into the brains of individuals with Parkinsons disease. The only previous trial using ES cells to treat Parkinsons began last year in Australia; participants there received stem cells from parthenogenetic embryosunfertilized eggs that are triggered in the lab to start embryonic development.

In the other Zhengzhou trial, surgeons will take retinal cells derived from ES cells and transplant them into the eyes of people with age-related macular degeneration. The team will follow a similar procedure to that of previous ES-cell trials carried out by researchers in the United States and South Korea.

Qi Zhou, a stem-cell specialist at the Chinese Academy of Sciences Institute of Zoology in Beijing, is leading both efforts. For the Parkinsons trial, his team assessed hundreds of candidates and have so far have picked ten who best match the ES cells in the cell bank, to reduce the risk of the patients bodies rejecting the cells.

The 2015 regulations state that hospitals planning to carry out stem-cell clinical work must use government-certified ES-cell lines and pass hospital-review procedures. Zhous team completed four years of work with a monkey model of Parkinsons, and has met the government requirements, he says.

Parkinsons disease is caused by a deficit in dopamine produced by brain cells. Zhous team will coax ES cells to develop into precursors to neurons, and will then inject them into the striatum, a central region of the brain implicated in the disease.

In their unpublished study of 15 monkeys, the researchers did not observe any improvements in movement at first, says Zhou. But at the end of the first year, the team examined the brains of half the monkeys and found that the stem cells had turned into dopamine-releasing cells. He says that they saw 50% improvement in the remaining monkeys over the next several years. We have all the imaging data, behavioural data and molecular data to support efficacy, he says. They are preparing a publication, but Zhou says that they wanted to collect a full five years worth of animal data.

Jeanne Loring, a stem-cell biologist at the Scripps Research Institute in La Jolla, California, who is also planning stem-cell trials for Parkinsons, is concerned that the Australian and Chinese trials use neural precursors and not ES-cell-derived cells that have fully committed to becoming dopamine-producing cells. Precursor cells can turn into other kinds of neurons, and could accumulate dangerous mutations during their many divisions, says Loring. Not knowing what the cells will become is troubling.

But Zhou and the Australian team defend their choices. Russell Kern, chief scientific officer of the International Stem Cell Corporation in Carlsbad, California, which is providing the cells for and managing the Australian trial, says that in preclinical work, 97% of them became dopamine-releasing cells.

Lorenz Studer, a stem-cell biologist at the Memorial Sloan Kettering Cancer Center in New York City who has spent years characterizing such neurons ahead of his own planned clinical trials, says that support is not very strong for the use of precursor cells. I am somewhat surprised and concerned, as I have not seen any peer-reviewed preclinical data on this approach, he says.

Studers and Lorings teams are part of an international consortium that coordinates stem-cell treatments for Parkinsons. In the next two years, five groups in the consortium plan to run trials using cells fully committed to becoming dopamine-producing cells.

Regenerative neurobiologist Malin Parmar, who heads one of the teams at Lund University in Sweden, says that the groups are all rapidly moving towards clinical trials, and this field will be very exciting in the coming years.

This article is reproduced with permission and wasfirst publishedon May 31, 2017.

Follow this link:
Trials of Embryonic Stem Cells to Launch in China - Scientific American

Texas May Be First To Allow Stem Cell Therapies For Desperate … – Vocativ

A bill may soon grant Texans greater access to unapproved but promising stem cell therapies, Stat News reports. Its passage would make Texasthe first state to back the technology, which has not been approved by federal regulators and many experts consider risky.

The bill, HB 810, is intended to give people with chronic diseases or terminal illnesses access to investigational stem cell treatments those that are being evaluated in clinical trials or that has in general not been approved by the FDA. With a doctors approval, patients who have had not had success withconventional treatments would be allowedto seek stem cell therapiesat any clinic that offers it, as long as the treatment is givenby a licensed physician and approved by an institutional review board.

Already, hundreds of largely unregulated clinics around the country are quietly operatingunder regulatory loopholes; few states have taken legal steps to advance or hinder patient access to them.

Texas has welcomed these clinics for years. In 2011, then-governor Rick Perry received an injection of stem cells intended to help heal his spine after spinal fusion surgery. Lets get Texas in on the ground floor and invest in adult stem cell research, the one area of that field that is actually proven to expedite cures, Perry said at the time, according to ABC News.

Stem cell therapy usually involves extracting a patients fat cells,processing and purifying the stem cellsoutside the body, then re-injecting them to the treatment site.Proponents of stem cell therapies claim that no regulators should be able to keep them from their own cells, which could potentially help ameliorate conditions such as Parkinsons, some types of blindness, or paralysis caused by injuries to the spinal cord. Indeed, some experiments have indicated that stem cells can in fact treat these conditions, including one that paused the progression of multiple sclerosis.

But experts warn that unregulated treatments put desperate patients at risk. They may come with unexpected side effects or adverse eventsone patient developed a spinal tumor after an injection of stem cells in Mexico; three women recently went blind in a clinical trial intended to improve their vision. Plus, theyre expensive and arent covered by insurance. Earlier this month, the president of the International Society for Stem Cell Research penned a letter to Texas legislators stating her opposition to HB 810, and two other pieces of pending legislation that would give patients easier access to unregulated treatments. These bills would cost more lives than they save and would be detrimental to the citizens of Texas.

Stem cell therapies are also at a crossroadsat the federal levellast year, the FDA pushed to crack down on these unregulated clinics, though later in 2016 a bill speeding the agencys review of stem cell treatments became law.

On May 12, the bill overwhelmingly passed the Texas House, without a single vote against. On May 24, it passed the state Senate, too. HB 810 will soon be on Governor Greg Abbotts desk to sign into law. Abbott is expected to do so as he has already expressed his support for the bill, Stat notes.

Originally posted here:
Texas May Be First To Allow Stem Cell Therapies For Desperate ... - Vocativ

Sickle cell cure is real, as this Kansas patient proves – Kansas City Star


Kansas City Star
Sickle cell cure is real, as this Kansas patient proves
Kansas City Star
Though pioneered three decades ago as the first sickle cell cure, bone marrow stem cell transplants remain underused especially for adult patients because of the risks involved, a lack of public awareness and a shortage of bone marrow donors for ...

Read this article:
Sickle cell cure is real, as this Kansas patient proves - Kansas City Star

Scientists find that smoking harms livers of unborn babies – BBC News


The National
Scientists find that smoking harms livers of unborn babies
BBC News
Scientists found that the cocktail of chemicals in cigarettes is particularly harmful to developing liver cells. They developed a method of studying the effects of maternal smoking on liver tissue using embryonic stem cells. The team, led by the ...
Smoking by pregnant women damages the liver cells of their unborn babiesThe National

all 4 news articles »

Read the rest here:
Scientists find that smoking harms livers of unborn babies - BBC News

This Immune Cell Could Promote Healthy Hair Growth – Science World Report


Science World Report
This Immune Cell Could Promote Healthy Hair Growth
Science World Report
On the other hand, the researchers discovered that when you knock this immune cell known as Tregs, the hair will not grow anymore. Professor Rosenblum said that it is as if the skin stem cells and Tregs have co-evolved so that the Tregs not only guard ...
Hair Growth Discovery Could Help Develop A Treatment For Hair LossIFLScience

all 16 news articles »

Read more:
This Immune Cell Could Promote Healthy Hair Growth - Science World Report

Seed Funding for a German Cell Therapy to Prevent Transplant … – Labiotech.eu (blog)

TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Grnderfonds.

TolerogenixXis a startup from the Heidelberg University Hospital that developspersonalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an impressive efficacy in preventing the rejection of kidney transplants without the need for immunosuppressive drugs.

The promising results seemto have convinced the German life sciences investorHigh-Tech Grnderfonds (HTGF),from which TolerogenixX has secured seed funding. HTGF is the first investor to jump in after pre-seed financing from the German Government. The funds, of an undisclosedamount, will help the startup make the preparations for a Phase II trial, planned for spring 2018.

TolerogenixXstechnology provides individualized immunosuppression, tailored specifically to the donor tissue. To do so,peripheral blood mononuclear cells (PBMCs) are harvested from the donor and treated with mitomycinCand then infused into the patient prior to the transplant.

Researchers at the University of Heidelberg discovered that mitomycin C inducesa change of behavior in dendritic cells, leading them to suppressT-cell responses. Immunological tests conducted during the trial revealed that the recipients had developed tolerance towards the donor.

The TolerogenixX technique represents a milestone in the field of individualized immunosuppression, saidPhilipp Rittershaus, Investment Manager at HTGF. Indeed, the therapy would allow transplantation without the need for immunosuppressants, which carry many severe side effects and leave patients completely unprotected against infections.

If everything goes well,TolerogenixX expects to complete Phase III andfile for approval in 2022. In addition, it will start a second program next year to treat autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus. The methodology would be very similar, just using autologous cells instead for the mitomycin C treatment instead of donor cells.

This is a real quantum leap in the treatment of transplant patients, said in a statement Matthias Schaier, CEO of TolerogenixX. In the future, it will no longer be necessary to take various medications with numerous side effects.

Images via crystal light / Shutterstock;TolerogenixX

Read the original post:
Seed Funding for a German Cell Therapy to Prevent Transplant ... - Labiotech.eu (blog)